Back to all articles
Comparisons

Semaglutide vs Tirzepatide vs Retatrutide: Which Weight Loss Peptide Wins in 2025?

Three generations of GLP-1 class peptides, three very different results. Head-to-head comparison of mechanism, weight loss %, side effects, and cost in India.

10 min read12 November 2025

The GLP-1 peptide class has produced three successive generations in under a decade, each significantly more effective than the last. Here's how they stack up for weight loss research.

Quick Comparison

Semaglutide: GLP-1 agonist only. ~15% average weight loss. Once weekly. Well-studied, longest track record.

Tirzepatide: GLP-1 + GIP dual agonist. ~22% average weight loss. Once weekly. Newer, stronger, similar side effect profile.

Retatrutide: GLP-1 + GIP + Glucagon triple agonist. ~24% average weight loss. Once weekly. Newest, most powerful, still in Phase 3 trials.

Mechanism Deep Dive

Why does adding receptors matter? Each receptor class does something different:

  • GLP-1 — suppresses appetite, slows gastric emptying, improves insulin response
  • GIP — enhances insulin secretion, regulates fat tissue metabolism, synergises with GLP-1 to boost appetite suppression beyond what either does alone
  • Glucagon — increases energy expenditure and fat oxidation. This is what retatrutide adds. You burn more calories at rest.

Weight Loss Results from Clinical Trials

  • Semaglutide 2.4mg (STEP 1 trial): 14.9% body weight at 68 weeks
  • Tirzepatide 15mg (SURMOUNT-1 trial): 22.5% body weight at 72 weeks
  • Retatrutide 12mg (TRIUMPH-1 trial): 24.2% body weight at 48 weeks (still descending)

Side Effect Comparison

All three share a similar GI side effect profile since they all hit GLP-1:

  • Nausea (most common, weeks 1–4, resolves with titration)
  • Reduced appetite (desired effect, but can become excessive)
  • Constipation or diarrhea (dose-dependent)

Retatrutide adds glucagon-related effects: mild heart rate increase (+5–7 bpm average in trials). This resolves and is well-tolerated in healthy research subjects.

Cost in India (Research Grade, PeptideBazaar)

  • Semaglutide 2mg vial: ₹3,200 (vs ₹18,000+ for prescription Ozempic)
  • Tirzepatide 5mg vial: ₹4,100 (vs ₹22,000+ for prescription Mounjaro)
  • Retatrutide 5mg vial: ₹4,400 (no prescription equivalent available)

Which Should You Research?

Semaglutide: Best if you want the most data behind it. Longest real-world track record. Good for metabolic research with moderate weight loss goals.

Tirzepatide: Step up if semaglutide plateaus or for faster weight reduction research. The dual mechanism is well-characterised.

Retatrutide: The cutting edge. Most powerful data, but shorter track record. For researchers who want maximum efficacy and are comfortable with newer compounds.

semaglutide vs tirzepatideretatrutide comparisonbest weight loss peptide india